Reuters logo
BRIEF-Synlogic receives orphan drug designation for SYNB1618, medicine for the treatment of Phenylketonuria
October 24, 2017 / 12:59 PM / 2 months ago

BRIEF-Synlogic receives orphan drug designation for SYNB1618, medicine for the treatment of Phenylketonuria

Oct 24 (Reuters) - Synlogic Inc

* Synlogic receives orphan drug designation for SYNB1618, a Synthetic Biotictm medicine for the treatment of Phenylketonuria Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below